Global Extracorporeal Membrane Oxygenation Market Set to Reach USD 903.6 Million by 2035, with a 4.7% CAGR

The global Extracorporeal Membrane Oxygenation market is estimated at USD 545.2 million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period 2025-2035. The ECMO market deals with medical devices to assist patients with cardiac and pulmonary failure. ECMO machines temporarily take over the action of either one or both organs by pumping blood outside the body, oxygenating it, and removing carbon dioxide. Generally, this treatment is found in critical care for patients who are undergoing a cardiac arrest, have severe pneumonia, or are in the phase of postoperative recovery. The most important drivers of the market include increases in the incidence of cardiopulmonary diseases, technological improvements in ECMO devices, and their increasing usage in neonatal and paediatric care. On the other hand, the high cost and requirement of specialist training present key challenges.

To explore in-depth analysis in this report - Request Free Sample Report

What are the Top Factors Driving Growth in the Extracorporeal Membrane Oxygenation Market?

Increasing rates of heart failure, respiratory failure, and acute respiratory distress syndrome (ARDS) are driving demand for ECMO systems.

The major driving factor is the growing incidences of heart failure, respiratory failure, and ARDS that are supporting the ECMO market. According to the Centers for Disease Control and Prevention (CDC), about 6.2 million adults suffer from heart failure in the U.S. The ECMO systems play a lifesaving role for those patients with severe cases of heart failure by serving as a bridge to recovery or, in some cases, assuring a needed heart transplant. Furthermore, ECMO serves patients with severe respiratory failure, especially when mechanical ventilation fails, like in the case of ARDS. Also, the COVID-19 pandemic provided a real showcase for ECMO in treating acute respiratory conditions and showed further weightage for adoption in hospitals. The rising incidences of these emergent diseases lead hospitals to invest in advanced ECMO systems, thereby influencing market growth.

Browse key industry insights spread across 220 pages with 120+ Market data tables and figures & charts from the report on the “Extracorporeal Membrane Oxygenation Market By Product Type (ECMO Machines [Portable Devices and Static Devices] and Software), By Application (Respiratory Applications, Cardiac Applications, and Extracorporeal Cardiopulmonary Resuscitation (ECPR)), By Modality (Veno-Arterial, Veno-Venous, and Others), By Patient Type (Neonates, Pediatric, and Adult), and By End-User (Hospitals, Clinics and Ambulatory Surgical Centers, and Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035”

Download an Exclusive Sample of the Report- https://www.metatechinsights.com/request-sample/1060

Improved device portability, miniaturization, and efficiency are enhancing the effectiveness and safety of ECMO therapy.

Increased device portability, miniaturization, and efficiency factors have significantly impacted the ECMO market. They are thus portraying a more effective and safer therapy. Traditional ECMO systems were bulky and cumbersome, confining them to a very special form of practice in the ICUs. The introduction of portable ECMOs, spurred on by advances in technology, could now be deployed in numerous regions, including small hospitals and emergencies. This aspect of portability is all the more important in terms of patient transport or urgent interventions. Such miniaturization reduces the trauma of blood flow and oxygenation onto the body of the patient, hence improving patient recovery. According to the National Heart, Lung, and Blood Institute (NHLBI), estimates suggest that about 40% of ARDS patients have to be put on mechanical ventilation, with ECMO known to improve survival chances in patients who critically need it.

What are the significant challenges impacting the Extracorporeal Membrane Oxygenation Market?

High Costs of Extracorporeal Membrane Oxygenation Hinder Patient Adoption and Treatment Compliance

The requirement for a team of specially trained healthcare professionals represents a severe limitation in the ECMO market. This involves highly complex procedures, requiring continuous monitoring and skilled personnel, including physicians, nurses, and respiratory therapists, for operation and management. Many hospitals, especially in rural and resource-limited settings, do not keep trained personnel, therefore limiting these hospitals in providing ECMO services. The shortage of trained professionals leads to delays in the treatment of patients. Moreover, the continuous education and training programs taken to maintain personnel competency can be expensive and cumbersome for healthcare facilities. As a result, the shortfall of sufficiently trained personnel has remained an inhibiting factor towards the widespread uptake and effective implementation of ECMO in various healthcare setups.

What are the attractive investment opportunities that can drive industry growth?

Telemedicine integration optimizes remote support and management of ECMO.

The adoption of telemedicine in ECMO is an opportunity to improve the patient’s outcome and the implementation of the system. By monitoring and assisting patients via apps, doctors can organize urgent in-person appointments and allocate resources to provide crucial support in high-risk cases without requiring face-to-face interaction. This technology provides the capabilities for real-time data exchange, resulting in enhanced collaboration and effective decision-making. Moreover, the use of telemedicine can improve the training and supervision of healthcare professionals responsible for the care of the ECMO patient and provide advice to the professional in the event of a doubt regarding the standard of care. With the demand for advanced respiratory support increasing, the use of telemedicine will be instrumental in making ECMO providers better placed to deliver this specialized care, increase their market niche, and therefore grow this market.

North America Plays a Crucial Role in the Extracorporeal Membrane Oxygenation Market Landscape

North America is the leading region in the Extracorporeal Membrane Oxygenation Market due to the highly developed infrastructure of healthcare systems, the high level of technology implementation, and the high incidence of diseases that often require ECMO, including respiratory and cardiac disorders. Many places have the best hospitals and research facilities, which help to create and undertake clinical research to improve the functionality of ECMO. Furthermore, early information dissemination to both healthcare practitioners and patients is a factor that drives the use of ECMO. Reimbursement policies and regulatory support are also being developed with an emphasis on ECMO, resulting in the availability of these procedures. Moreover, training and education always help medical professionals enhance their proficiency levels in ECMO. Overall, the considerations show that North America is a key player in the global ECMO market in terms of growth and development in patient treatment.

Read more about the report: https://www.metatechinsights.com/industry-insights/extracorporeal-membrane-oxygenation-market-1060

Europe Holds a Significant Share of the Extracorporeal Membrane Oxygenation Market

The European Extracorporeal Membrane Oxygenation Market growth can be linked to a higher number of patients diagnosed with respiratory and cardiac diseases including ARDS and heart failure. Major economies like Germany, the UK, and France with well-developed medical infrastructure are investing in advanced life support equipment and in particular, ECMO. This investment further enjoys the backing of increased knowledge by the providers and patients of the benefits of ECMO in critical care. With improving survival rates, there is a greater realization among more hospitals that ECMO must be integrated into their treatments. Furthermore, continued education and training of personnel in the medical field contribute to the proper utilization of ECMO ensuring that it is being used more widely. In summary, with the increase in technology, improvement of patients, and rise in awareness of the rescued patients in the past few years, the ECMO market continues to expand in several countries in Europe.

Competitive Landscape

Extracorporeal Membrane Oxygenation (ECMO) Market is highly competitive propelling developments in critical care technology. Key players including Terumo Corporation, Getinge AB, LivaNova PLC, and Medtronic Plc impact a significant portion of this market with their sophisticated ECMO systems. Through collaborations, Xenios AG and MicroPort Scientific Corporation are diversifying their product offerings. Getinge launched cutting-edge ECMO devices to increase patient survival, while LivaNova is expanding its line of cardiopulmonary goods to include children's oxygenator technology. Alung Technologies and CytoSorbents Corporation have created competition in the industry by introducing inexpensive devices. These facilitate expansion and generate innovation in patient care and longer-term development.

Recent Developments

• In September 2024, Medtronic released the VitalFlow™, a revolutionary Extracorporeal Membrane Oxygenation (ECMO) device meant to improve respiratory assistance for critically ill patients. This new system aims to enhance patient outcomes by utilizing sophisticated technology, giving healthcare providers a more efficient treatment choice in critical care conditions.

Report Coverage:

By Product Type

• ECMO Machines
  • Portable Devices
  • Static Devices
• Software

By Application

• Respiratory Applications
• Cardiac Applications
• Extracorporeal Cardiopulmonary Resuscitation (ECPR)

By Modality

• Veno-Arterial
• Veno-Venous
• Others

By Patient Type

• Neonates
• Pediatric
• Adult

By End-User

• Hospitals
• Clinics and Ambulatory Surgical Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic Plc
• Getinge AB
• LivaNova PLC
• MicroPort Scientific Corporation
• Abbott Laboratories
• Terumo Corporation
• Alung Technologies, Inc.
• EUROSETS S.r.l.
• Nipro Corporation
• Fresenius Medical Care AG & Co. KGaA
• Baxter International Inc.
• Orion Health Pty Ltd.
• Xenios AG
• Biomedica Beteiligungs- und Handels GmbH
• CytoSorbents Corporation